Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 10Phase 1 5Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Colorectal Neoplasms 15Stomach Neoplasms 11Colonic Neoplasms 7Carcinoma, Hepatocellular 7Rectal Neoplasms 4Pancreatic Neoplasms 3Neoplasms 3Biliary Tract Neoplasms 3Lymphoma, Large B-Cell, Diffuse 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Adenocarcinoma 2Vipoma 1Somatostatinoma 1Resected Liver Metastases From Colorectal Cancer 1Recurrence 1Quality of Life 1Pathologic Complete Response 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Insulinoma 1Immunotherapy Gastrict Cancer 1HER2-positive Gastric Cancer 1Glucagonoma 1Gastroesophageal Junction Adenocarcinoma 1Gastrinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Oxaliplatin 2Fluorouracil 2rubitecan 1nimotuzumab 1halofantrine 1gallium 68 PSMA-11 1camrelizumab 1apatinib 1S 1 (combination) 1Radiotherapy 1Radiosurgery 1Radiation 1Photochemotherapy 1Nadroparin 1Heparin, Low-Molecular-Weight 1Gastrectomy 1Esophagectomy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1Capecitabine 1CP protocol 1Brachytherapy 1Atrasentan 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Adenocarcinoma × Oxaliplatin × Clear all
NCT04208347 2026-01-23

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Ruijin Hospital

Phase 2/3 Active not recruiting
580 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01523015 2013-02-05

Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction

Medical University of Lublin

Phase 2/3 Unknown
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡